Tylenol is a pharmaceutical atrocity

Written by Robert Yoho, MD on September 7, 2026. Posted in Current News

The most-used pediatric drug on earth entered universal use with two days of observation per study, and the question of what repeated exposure does to a growing brain over years was never raised.

American pediatrics swapped its standard fever drug between 1980 and 1986. Aspirin, which it gave up, had been evaluated in randomized trials with more than 100,000 participants and hundreds of thousands of person-years, with death, stroke, and bleeding as endpoints. Tylenol, which it adopted, had 52 safety experiments behind it, a median follow-up of 48 hours, and no measurement of neurodevelopment.

● The National Institutes of Health LiverTox database reports that no convincing case of aspirin-induced acute liver failure has ever been published. Acetaminophen accounts for 42 percent of acute liver failure cases in the United States.

● At the labeled maximum of 4 grams of Tylenol per day, 31 to 44 percent of healthy volunteers had liver enzymes more than three times normal within two weeks. None of the placebo subjects did.

● In a randomized crossover trial of hypertensive patients, the same 4 grams raised systolic blood pressure by 4.7 mmHg.

● Acetaminophen lacks peripheral anti-inflammatory action. That is why it does nothing measurable for arthritis, and the trials show exactly that: a 3-point improvement on a 100-point pain scale.

● It does nothing for acute back pain either. A trial of 1,652 patients found that the median time to recovery was 17 days on the drug and 16 days on placebo.

● A Cochrane review of 728 newborns found that it does not relieve procedural pain and, in one trial, worsened the response to a later heel stick.

● More than 600 products contain it. In 2011, the FDA capped prescription combinations at 325 mg, writing that anything above that lacked a sufficient margin of safety, then left the 500 mg and 650 mg bottles on the open shelf, where they sit today.

● Aspirin has fallen from co-leader of the analgesic market to third place, and low-dose aspirin for heart protection has more than halved since 2018.

● Pharma attacks cheaper competitors. I can prove it with guilty pleas rather than inference, and the relevant section is below.

The trade

Somebody made a decision about American children between 1980 and 1986, and almost nobody now remembers it.

Before that, a feverish child in this country received aspirin. Afterward, the same child received Tylenol. The switch was nearly total and permanent. Reported cases of Reye syndrome peaked at 555 in 1980. The Centers for Disease Control published its case-control findings that year. The Secretary of Health and Human Services announced in June 1982 that warnings were warranted, and the final labeling rule appeared in March 1986. By 1988, reported Reye cases had fallen to 20.

Pediatric ibuprofen could not have filled the gap. It was not approved as a prescription drug for American children until September 1989 and was not sold over the counter until June 1995. For most of a decade, there was exactly one substitute available, acetaminophen.

Set aside for a moment whether the Reye warnings were correct. Instead, look at what medicine gave up and what it took on, and how well it knew each.

By 1980, aspirin had been in use for eighty years, and by now it has been tested in randomized trials enrolling well over 100,000 participants and followed for several hundred thousand person-years, with hard adjudicated endpoints, including death.

We know what it does and what it costs. In people with established cardiovascular disease, it prevents serious vascular events at a rate of 6.69 percent a year, compared with 8.19 percent on control, an absolute reduction of 1.49 percent a year.

The bleeding price is quantified: about 1.2 excess major gastrointestinal bleeds per 1,000 patient-years in a meta-analysis of 22 randomized trials covering 75,005 people on low-dose aspirin. Those are unpleasant numbers. They are not mysterious numbers. Somebody counted them.

read the rest at robertyoho.substack.com